Amendment No. 1 to Manufacture and Supply Agreement between Luitpold Pharmaceuticals, Inc. and BioMimetic Therapeutics, Inc.

Contract Categories: Business Operations › Supply Agreements
Summary

This amendment extends the original Manufacture and Supply Agreement between Luitpold Pharmaceuticals, Inc. and BioMimetic Therapeutics, Inc. The new term lasts until December 31, 2026, with automatic five-year renewals unless either party gives six months' notice to end the agreement. All other terms of the original agreement remain unchanged.

Read More Arrow
EX-10.25 34 file026.htm LETTER OF AGREEMENT 
  Exhibit 10.25 AMENDMENT NO. 1 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 1 is made to the Manufacture and Supply Agreement made December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals, Inc., a New York corporation ("Luitpold") and BioMimetic Therapeutics, Inc. (formerly BioMimetic Pharmaceuticals, Inc.), a Delaware corporation ("BMTI") (each, individually a "Party" and collectively, the "Parties") as of this 21th day of December, 2005. WHEREAS, the Term of the Agreement was to extend until the seventh anniversary date of the Effective Date of the Agreement; and WHEREAS, the Parties have agreed to extend the Term of the Agreement; NOW, THEREFORE, in consideration of the mutual premises, covenants, and agreements hereinafter set forth, the sufficiency of which is hereby acknowledged, the Parties to the Agreement, intending to be bound, mutually agree as follows: 1. Section 11.1 of the Agreement is amended as follows: "The term of this Agreement shall be for a period beginning on the Effective Date and shall continue until December 31, 2026 (the "Initial Term"). This Agreement shall renew at the end of the Initial Term for subsequent five (5) year renewal terms (each, a "Renewal Term," and together with the Initial Term, the "Term"), unless either party gives at least six (6) months notice of intent not to renew." 2. Except as otherwise expressly amended above, all provisions of the Agreement shall continue to remain in full force and effect.  IN WITNESS WHEREOF, Luitpold and BMTI have entered into this Amendment No. 1 effective as of the date hereinabove written, each by a duly authorized officer, in duplicate originals. LUITPOLD PHARMACEUTICALS, INC. BIOMIMETIC THERAPEUTICS, INC. By:/s/ Mary Jane Helenek By:/s/ Samuel Lynch ------------------------------------------- ------------------------ Mary Jane Helenek, R. Ph., M.S., M.B.A. Samuel Lynch, D.D.S. Preisedent and CEO President and CEO - 2 -